Formoterol/fluticasone propionate - Vectura

Drug Profile

Formoterol/fluticasone propionate - Vectura

Alternative Names: Abriff; Fluticasone propionate/formoterol fumarate; Fluticasone/formoterol; Flutiform; flutiform K-Haler; Flutiformo; Flutiform™ HFA-MDI; Formoterol fumarate/fluticasone propionate; FP/FORM - Vectura; Iffeza; KRP-108

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma PLC
  • Developer Kyorin Pharmaceutical; Mundipharma International; Mundipharma Research; SkyePharma PLC; Vectura
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Oct 2017 Chemical structure information added
  • 04 Oct 2017 Formoterol/fluticasone propionate breath-actuated inhaler for Asthma (flutiform® K-Haler®) gets approval in the UK (Reference Member State) through the European Decentralised procedure
  • 10 Sep 2017 Efficacy data from a clinical trial in Asthma and Chronic obstructive pulmonary disease released by Mundipharma Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top